| Summary: | Dupilumab (Dupixent) is indicated for use in adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids (TCS). The dosage form is 150 mg/mL solution in a pre-filled syringe, intended for patients to self-administer subcutaneously. The recommended dosage for adult patients is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg injected every other week. At the submitted price of $1,153.85 per 300 mg dose, the first-year cost of dupilumab is $31,154, and $30,000 annually thereafter. The manufacturer submitted a cost-utility analysis (CUA) of dupilumab as an add-on to current standard of care (SOC) in patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies
|
|---|